Lung cancer screening: the way forward

To take lung cancer screening into national programmes, we first have to answer the question whether low-dose computed tomography (LDCT) screening and treatment of early lesions will decrease lung cancer mortality compared with a control group, to accurately estimate the balance of benefits and harm...

Descripción completa

Detalles Bibliográficos
Autores principales: Field, J K, Duffy, S W
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Minireview
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527832/
https://www.ncbi.nlm.nih.gov/pubmed/18665179
http://dx.doi.org/10.1038/sj.bjc.6604509
Descripción
Sumario:To take lung cancer screening into national programmes, we first have to answer the question whether low-dose computed tomography (LDCT) screening and treatment of early lesions will decrease lung cancer mortality compared with a control group, to accurately estimate the balance of benefits and harms, and to determine the cost-effectiveness of the intervention.

Ejemplares similares